Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Dana-Farber Cancer Institute · Institut Gustave Roussy · +24 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
937
total citations
- FWCI
- 107.96
- Percentile
- 100%
- References
- 32
Citations per year
Authors
23- TKToni K. ChoueiriCorresponding
Dana-Farber Cancer Institute
- BEBernard Escudier
Institut Gustave Roussy
- TPThomas Powles
University College London, The Royal Free Hospital, Cancer Research UK, Queen Mary University of London
- NMNizar M. Tannir
The University of Texas MD Anderson Cancer Center
- PNPaul N. Mainwaring
Cancer Council Queensland
Topics & keywords
Topics
Keywords
- Cabozantinib
- Everolimus
- Meteor (satellite)
- Renal cell carcinoma
- Medicine
- Open label
- Oncology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.